In order to start dissecting the influence of Ltbp4 polymorphism on the efficacy of Givinostat in DMD mouse models, we first set out to characterize the effect of our HDAC inhibitor in mdx mice. The gene discussed is LTBP4; the disease is Duchenne muscular dystrophy.